Top 5 Stocks to Buy Now
→ Trump's gold order: the announcement they won't put on the front page (From Reagan Gold Group) (Ad)tc pixel Free TSTL Stock Alerts

Tristel (TSTL) Competitors

Tristel logo
GBX 387.50 0.00 (0.00%)
As of 06/19/2026 11:40 AM Eastern
Compare

TSTL vs. AMS, SPEC, BVC, AKR, and ODX

Should you buy Tristel stock or one of its competitors? MarketBeat compares Tristel with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tristel include Advanced Medical Solutions Group (AMS), INSPECS Group (SPEC), BATM Advanced Communications (BVC), Akers Biosciences (AKR), and Omega Diagnostics Group (ODX). These companies are all part of the "medical instruments & supplies" industry.

How does Tristel compare to Advanced Medical Solutions Group?

Tristel (LON:TSTL) and Advanced Medical Solutions Group (LON:AMS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Advanced Medical Solutions Group has higher revenue and earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than Advanced Medical Solutions Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M3.75£6.54M£16.2423.86
Advanced Medical Solutions Group£228.94M2.21£11.22M£4.5251.44

Tristel has a beta of 0.333, meaning that its share price is 67% less volatile than the broader market. Comparatively, Advanced Medical Solutions Group has a beta of 0.709, meaning that its share price is 29% less volatile than the broader market.

Tristel presently has a consensus price target of GBX 400, suggesting a potential upside of 3.23%. Advanced Medical Solutions Group has a consensus price target of GBX 270.25, suggesting a potential upside of 16.24%. Given Advanced Medical Solutions Group's stronger consensus rating and higher possible upside, analysts clearly believe Advanced Medical Solutions Group is more favorable than Tristel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Advanced Medical Solutions Group
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

21.6% of Tristel shares are owned by institutional investors. Comparatively, 21.9% of Advanced Medical Solutions Group shares are owned by institutional investors. 21.0% of Tristel shares are owned by company insiders. Comparatively, 4.0% of Advanced Medical Solutions Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Advanced Medical Solutions Group's average media sentiment score of 0.73 beat Tristel's score of 0.00 indicating that Advanced Medical Solutions Group is being referred to more favorably in the news media.

Company Overall Sentiment
Tristel Neutral
Advanced Medical Solutions Group Positive

Tristel has a net margin of 15.88% compared to Advanced Medical Solutions Group's net margin of 4.35%. Tristel's return on equity of 23.64% beat Advanced Medical Solutions Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
Advanced Medical Solutions Group 4.35%3.87%2.35%

Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.7%. Advanced Medical Solutions Group pays an annual dividend of GBX 2.68 per share and has a dividend yield of 1.2%. Tristel pays out 87.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Advanced Medical Solutions Group pays out 59.3% of its earnings in the form of a dividend.

Summary

Advanced Medical Solutions Group beats Tristel on 10 of the 17 factors compared between the two stocks.

How does Tristel compare to INSPECS Group?

INSPECS Group (LON:SPEC) and Tristel (LON:TSTL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

INSPECS Group presently has a consensus price target of GBX 60, suggesting a potential downside of 41.18%. Tristel has a consensus price target of GBX 400, suggesting a potential upside of 3.23%. Given Tristel's higher probable upside, analysts plainly believe Tristel is more favorable than INSPECS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
INSPECS Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Tristel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Tristel has a net margin of 15.88% compared to INSPECS Group's net margin of -2.67%. Tristel's return on equity of 23.64% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-2.67% -6.07% 0.45%
Tristel 15.88%23.64%9.89%

Tristel has lower revenue, but higher earnings than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£191.70M0.54-£4.11M-£9.40N/A
Tristel£49.54M3.75£6.54M£16.2423.86

0.4% of INSPECS Group shares are owned by institutional investors. Comparatively, 21.6% of Tristel shares are owned by institutional investors. 21.0% of INSPECS Group shares are owned by insiders. Comparatively, 21.0% of Tristel shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

INSPECS Group has a beta of 1.611, suggesting that its share price is 61% more volatile than the broader market. Comparatively, Tristel has a beta of 0.333, suggesting that its share price is 67% less volatile than the broader market.

In the previous week, INSPECS Group had 2 more articles in the media than Tristel. MarketBeat recorded 2 mentions for INSPECS Group and 0 mentions for Tristel. INSPECS Group's average media sentiment score of 0.18 beat Tristel's score of 0.00 indicating that INSPECS Group is being referred to more favorably in the media.

Company Overall Sentiment
INSPECS Group Neutral
Tristel Neutral

Summary

Tristel beats INSPECS Group on 10 of the 16 factors compared between the two stocks.

How does Tristel compare to BATM Advanced Communications?

Tristel (LON:TSTL) and BATM Advanced Communications (LON:BVC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Tristel has a beta of 0.333, meaning that its share price is 67% less volatile than the broader market. Comparatively, BATM Advanced Communications has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

In the previous week, Tristel's average media sentiment score of 0.00 equaled BATM Advanced Communications'average media sentiment score.

Company Overall Sentiment
Tristel Neutral
BATM Advanced Communications Neutral

Tristel has a net margin of 15.88% compared to BATM Advanced Communications' net margin of -14.90%. Tristel's return on equity of 23.64% beat BATM Advanced Communications' return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
BATM Advanced Communications -14.90%-22.13%0.58%

21.6% of Tristel shares are owned by institutional investors. Comparatively, 16.6% of BATM Advanced Communications shares are owned by institutional investors. 21.0% of Tristel shares are owned by company insiders. Comparatively, 31.0% of BATM Advanced Communications shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Tristel currently has a consensus price target of GBX 400, suggesting a potential upside of 3.23%. Given Tristel's higher possible upside, analysts clearly believe Tristel is more favorable than BATM Advanced Communications.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
BATM Advanced Communications
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Tristel has higher earnings, but lower revenue than BATM Advanced Communications. BATM Advanced Communications is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M3.75£6.54M£16.2423.86
BATM Advanced Communications£123.20M0.39-£278.26K-£4.20N/A

Summary

Tristel beats BATM Advanced Communications on 9 of the 14 factors compared between the two stocks.

How does Tristel compare to Akers Biosciences?

Akers Biosciences (LON:AKR) and Tristel (LON:TSTL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

21.6% of Tristel shares are owned by institutional investors. 21.0% of Tristel shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Akers Biosciences' average media sentiment score of 0.00 equaled Tristel'saverage media sentiment score.

Company Overall Sentiment
Akers Biosciences Neutral
Tristel Neutral

Tristel has higher revenue and earnings than Akers Biosciences. Akers Biosciences is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akers Biosciences£2.32M0.00N/A-£129.60N/A
Tristel£49.54M3.75£6.54M£16.2423.86

Tristel has a net margin of 15.88% compared to Akers Biosciences' net margin of 0.00%. Tristel's return on equity of 23.64% beat Akers Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Akers BiosciencesN/A N/A N/A
Tristel 15.88%23.64%9.89%

Tristel has a consensus target price of GBX 400, suggesting a potential upside of 3.23%. Given Tristel's stronger consensus rating and higher probable upside, analysts plainly believe Tristel is more favorable than Akers Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akers Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Tristel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Tristel beats Akers Biosciences on 10 of the 10 factors compared between the two stocks.

How does Tristel compare to Omega Diagnostics Group?

Tristel (LON:TSTL) and Omega Diagnostics Group (LON:ODX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Tristel presently has a consensus target price of GBX 400, indicating a potential upside of 3.23%. Given Tristel's stronger consensus rating and higher probable upside, equities research analysts plainly believe Tristel is more favorable than Omega Diagnostics Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tristel
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Omega Diagnostics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

21.6% of Tristel shares are held by institutional investors. Comparatively, 29.8% of Omega Diagnostics Group shares are held by institutional investors. 21.0% of Tristel shares are held by insiders. Comparatively, 50.6% of Omega Diagnostics Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Tristel has a net margin of 15.88% compared to Omega Diagnostics Group's net margin of -51.15%. Tristel's return on equity of 23.64% beat Omega Diagnostics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Tristel15.88% 23.64% 9.89%
Omega Diagnostics Group -51.15%-29.14%-10.53%

Tristel has a beta of 0.333, meaning that its stock price is 67% less volatile than the broader market. Comparatively, Omega Diagnostics Group has a beta of 3.85, meaning that its stock price is 285% more volatile than the broader market.

Tristel has higher revenue and earnings than Omega Diagnostics Group. Omega Diagnostics Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tristel£49.54M3.75£6.54M£16.2423.86
Omega Diagnostics Group£7.55M0.00-£3.17M-£0.01N/A

In the previous week, Tristel's average media sentiment score of 0.00 equaled Omega Diagnostics Group'saverage media sentiment score.

Company Overall Sentiment
Tristel Neutral
Omega Diagnostics Group Neutral

Summary

Tristel beats Omega Diagnostics Group on 9 of the 12 factors compared between the two stocks.

Get Tristel News Delivered to You Automatically

Sign up to receive the latest news and ratings for TSTL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TSTL vs. The Competition

Export
MetricTristelMedical Instruments & Supplies IndustryMedical SectorLON Exchange
Market Cap£185.95M£3.04B£6.42B£2.88B
Dividend Yield3.69%2.03%2.68%6.15%
P/E Ratio23.8616.4224.78366.85
Price / Sales3.7573.94553.9186,444.11
Price / Cash20.96146.5445.0727.85
Price / Book5.672.2210.808.01
Net Income£6.54M£99.80M£3.57B£5.89B
7 Day Performance0.26%-0.34%0.72%0.07%
1 Month Performance-0.64%-1.63%0.41%0.93%
1 Year Performance6.16%-8.08%29.34%72.13%

Tristel Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TSTL
Tristel
N/AGBX 387.50
flat		GBX 400
+3.2%		+6.2%£185.95M£49.54M23.86208
AMS
Advanced Medical Solutions Group
1.7229 of 5 stars		GBX 220.50
flat		GBX 270.25
+22.6%		+12.0%£478.99M£228.94M48.7810
SPEC
INSPECS Group
0.6173 of 5 stars		GBX 82.50
-2.4%		GBX 60
-27.3%		+112.5%£83.88M£191.70MN/A1,673
BVC
BATM Advanced Communications
0.8276 of 5 stars		GBX 12.90
+2.0%		N/A-14.2%£43.87M£123.20MN/A980
AKR
Akers Biosciences
N/AN/AN/AN/A£21.64M£2.32MN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:TSTL) was last updated on 6/21/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
A huge SpaceX error just led one stock to 3X move!
SPCE surged roughly 300% in a single week after investors hunting SpaceX exposure piled into the wrong ticker....
InvestPub | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel